The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Development and Potential Clinical Uses of Human Prolactin Receptor Antagonists
Abstract
There is a large body of literature showing that prolactin (PRL) exerts growth-promoting activities in breast cancer, and possibly in prostate cancer and prostate hyperplasia. In addition, increasing evidence argues for the involvement of locally produced (autocrine) PRL, perhaps even more than pituitary-secreted (endocrine) PRL, in tumor growth. Because dopamine analogs are unable to inhibit PRL production in extrapituitary sites, alternative strategies need investigation. To that end, several PRL receptor antagonists have been developed by introducing various mutations into its natural ligands. For all but one of these analogs, the mechanism of action involves a competition with endogenous PRL for receptor binding. Such compounds are thus candidates to counteract the undesired actions of PRL, not only in tumors, but also in dopamine-resistant prolactinomas. In this review, we describe the different versions of antagonists that have been developed, with emphasis on the controversies regarding their characterization, and the limits for their potential development as a drug. The most recently developed antagonist, Delta1-9-G129R-hPRL, is the only one that is totally devoid of residual agonistic activity, meaning it acts as pure antagonist. We discuss to what extent this new molecule could be considered as a lead compound for inhibiting the actions of human PRL in the above-mentioned diseases. We also speculate on the multiple questions that could be addressed with respect to the therapeutic use of PRL receptor antagonists in patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prolactin: structure, function, and regulation of secretion
Freeman, M. E., Kanyicska, B., Lerant, A., & Nagy, G. (2000) · Physiological Reviews · doi:10.1152/physrev.2000.80.4.1523 · Cited by 2,457 · cited 2×
“The pituitary transcription factor 1 (Pit-1) is a major player in the regulation of PRL gene transcription in the pituitary (22).”
Cited by
Advances in the Treatment of Prolactinomas
Gillam, M. P., Molitch, M. E., Lombardi, G., & Colao, A. (2006) · Endocrine Reviews · doi:10.1210/er.2005-9998 · Cited by 824
What Can We Learn from Rodents about Prolactin in Humans?
Ben-Jonathan, N., LaPensee, C. R., & LaPensee, E. W. (2008) · Endocrine Reviews · doi:10.1210/er.2007-0017 · Cited by 523
Hyperprolactinemia and Prolactinomas
Mancini, T., Casanueva, F. F., & Giustina, A. (2008) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2007.10.013 · Cited by 256
Adverse effects of prolactin in rodents and humans: breast and prostate cancer
Harvey, P. W., Everett, D. J., & Springall, C. J. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881107082624 · Cited by 72
Montejo, Á. L., Arango, C., Bernardo, M., Carrasco, J. L., Crespo-Facorro, B., Cruz, J. J., del Pino, J., García Escudero, M. A., García Rizo, C., González-Pinto, A., et al. (2016) · Revista de Psiquiatría y Salud Mental · doi:10.1016/j.rpsm.2015.11.003 · Cited by 55
Prolactin in Human Reproduction
Molitch, M. E. (2009) · Yen & Jaffe's Reproductive Endocrinology · doi:10.1016/b978-1-4160-4907-4.00003-6 · Cited by 31
Metadata
- Authors
- Goffin, V., Bernichtein, S., Touraine, P., & Kelly, P. A.
- Venue
- Endocrine Reviews
- Publisher
- The Endocrine Society
- Published
- 2005-04-06
- Volume
- 26
- Issue
- 3
- Pages
- 400-422
- ISSN
- 0163-769X (ISSN-L)
- 1945-7189
- OpenAlex
- W2132807638
- Cited by
- 199
- References
- 1
- FWCI
- 10.40
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.